Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC.
暂无分享,去创建一个
Joe Y. Chang | Xiaodong Zhang | Steven H. Lin | X. Zhu | Z. Liao | J. Heymach | O. Gjyshi | A. Tsao | Aileen B Chen | F. Fossella | C. Gay | A. Elhammali | Ting Xu | Charles Lu | Percy Lee | S. Gandhi | Q. Nguyen | D. Boyce-Fappiano | S. Chun | T. Xu | J. Heymach
[1] Z. Liao,et al. Proton therapy for locally advanced non-small cell lung cancer. , 2020, The British journal of radiology.
[2] K. Forster,et al. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Joe Y. Chang,et al. Proton therapy for non-small cell lung cancer: the road ahead. , 2019, Translational lung cancer research.
[4] Zhongxing Liao,et al. Clinical outcomes after intensity-modulated proton therapy with concurrent chemotherapy for inoperable non-small cell lung cancer. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[5] R. Mohan,et al. Validation of Effective Dose as a Better Predictor of Radiation Pneumonitis Risk Than Mean Lung Dose: Secondary Analysis of a Randomized Trial. , 2019, International journal of radiation oncology, biology, physics.
[6] D. Planchard,et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.
[7] Radhe Mohan,et al. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Tarek Mekhail,et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[9] M. Socinski,et al. Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Radhe Mohan,et al. Proton therapy - Present and future. , 2017, Advanced drug delivery reviews.
[11] J. Galvin,et al. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Joe Y. Chang,et al. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[13] W. Curran,et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.
[14] Heng Li,et al. Clinical implementation of intensity modulated proton therapy for thoracic malignancies. , 2014, International journal of radiation oncology, biology, physics.
[15] Heng Li,et al. Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting. , 2014, Practical radiation oncology.
[16] Radhe Mohan,et al. Robust optimization of intensity modulated proton therapy. , 2012, Medical physics.
[17] Joe Y. Chang,et al. Phase 2 study of high‐dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer , 2011, Cancer.
[18] Radhe Mohan,et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. , 2010, International journal of radiation oncology, biology, physics.
[19] Radhe Mohan,et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. , 2006, International journal of radiation oncology, biology, physics.